Myris Therapeutics is developing ultra-high DAR ADCs to enable novel precision medicine treatments for cancer

CAR-T Digest - August 2020

20 Feb 2025: Myris Therapeutics is developing ultra-high DAR ADCs to enable novel precision medicine treatments for cancer

Myris Therapeutics, formerly BioHybrid Solutions, has emerged from stealth with a focus on ultra-high Drug Antibody Ratio (DAR) ADCs for oncology
Its proprietary polymer chemistry enables DARs of 50-300, significantly higher than current standards, expanding precision therapy options
The company stated in a press release that its innovative approach dramatically expands the range of possible payloads and precision therapy opportunities.
Furthermore, company highlighted that this breakthrough enables the use of many clinically validated small molecules that were previously not amenable to inclusion in ADCs due to their pharmacology or therapeutic index
Myris ADCs utilize the ATRP ‘growing from’ technology to build polymer bottlebrushes on which payloads are attached
The company’s lead program, funded by the U.S. Department of Defense, has successfully nominated a development candidate